Bellus falls to GSK for $2bn
A deal for a mid-stage company bodes well for the biotech sector, but GSK will have to make chronic cough pay.
Biopharma’s stock market winners of 2021 revealed
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Merck’s cough win might be irrelevant
Gefapixant works – just not all that well. Will the commercial return make the clinical effort worthwhile?
Bellus chokes in chronic cough
After Merck’s success with a P2X3 inhibitor hopes were high for Bellus’s similar compound. They are now dashed.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Merck’s cough success highlights pipeline hopes
Good news for patients whose cough is not caused by Covid-19: Merck’s chronic cough pill is a step closer to market. But tolerability questions remain.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
